Clinical Trial Update: Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE

View source ↗

Summary

Completed Canadian registry study evaluating edoxaban (Lixiana) in patients with atrial fibrillation or atrial flutter and valvular heart disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Atrial Flutter
• Valvular Heart Disease

Drugs mentioned

• Lixiana (edoxaban)

Snippet

Sponsor: Montreal Heart Institute | Conditions: Atrial Fibrillation and Flutter, Valvular Heart Disease | Status: COMPLETED